Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells
…, Y Wang, D Li, W Liu, Y Zhang, L Shen, W Han, L Shen… - Science, 2020 - science.org
INTRODUCTION In cellular immunity, cytotoxic T lymphocytes (CTLs) and natural killer (NK)
cells use perforin to deliver serine protease granzymes into target cells to kill them. …
cells use perforin to deliver serine protease granzymes into target cells to kill them. …
Epigenetic therapy inhibits metastases by disrupting premetastatic niches
Cancer recurrence after surgery remains an unresolved clinical problem 1 , 2 – 3 . Myeloid
cells derived from bone marrow contribute to the formation of the premetastatic …
cells derived from bone marrow contribute to the formation of the premetastatic …
An effective heuristic algorithm for the traveling-salesman problem
S Lin, BW Kernighan - Operations research, 1973 - pubsonline.informs.org
This paper discusses a highly effective heuristic procedure for generating optimum and near-optimum
solutions for the symmetric traveling-salesman problem. The procedure is based …
solutions for the symmetric traveling-salesman problem. The procedure is based …
Circulating PD‐L 1 in NSCLC patients and the correlation between the level of PD‐L 1 expression and the clinical characteristics
…, X Chen, J Han, X Ma, G Tian, D Wu, L Shen… - Thoracic …, 2015 - Wiley Online Library
Background The programmed cell death‐1/programmed cell death‐1 ligand ( PD ‐1/ PD ‐ L
1) pathway plays a crucial role in tumor evasion. This study evaluated the association …
1) pathway plays a crucial role in tumor evasion. This study evaluated the association …
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer …
…, E Van Cutsem, A Feyereislova, HC Chung, L Shen… - The Lancet, 2010 - thelancet.com
Background Trastuzumab, a monoclonal antibody against human epidermal growth factor
receptor 2 (HER2; also known as ERBB2), was investigated in combination with …
receptor 2 (HER2; also known as ERBB2), was investigated in combination with …
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma …
Background First-line chemotherapy for advanced or metastatic human epidermal growth
factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma …
factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma …
An efficient heuristic procedure for partitioning graphs
BW Kernighan, S Lin - The Bell system technical journal, 1970 - ieeexplore.ieee.org
We consider the problem of partitioning the nodes of a graph with costs on its edges into
subsets of given sizes so as to minimize the sum of the costs on all edges cut. This problem …
subsets of given sizes so as to minimize the sum of the costs on all edges cut. This problem …
Computer solutions of the traveling salesman problem
S Lin - Bell System Technical Journal, 1965 - Wiley Online Library
Two algorithms for solving the (symmetric distance) traveling salesman problem have been
programmed for a high‐speed digital computer. The first produces guaranteed optimal …
programmed for a high‐speed digital computer. The first produces guaranteed optimal …
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
…, N Li, S Lonardi, O Kolesnik, O Barajas, Y Bai, L Shen… - Nature, 2021 - nature.com
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …
Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer
…, SH Lee, J Bennouna, K Kato, L Shen… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited
treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, …
treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, …